Under U.S. GAAP, the default treatment of R&D is expense as incurred under ASC 730 — and that default is correct most of the time. The questions worth careful thought are the exceptions: acquired IPR&D in a business combination versus an asset acquisition, the alternative-future-use test for tangible R&D assets, internal-use software under ASC 350-40, pre-commercial inventory once approval becomes probable, and the upfront fees and milestones inside collaboration agreements. Each has a defensible answer; what makes the answer hold up in audit is the contemporaneous documentation behind it.
For most biotech finance teams, the R&D accounting policy fits in one sentence: expense as incurred. ASC 730 makes that the default, and the financial statements of nearly every pre-commercial biotech reflect it. The reason the policy still consumes audit time is that the exceptions to the default — narrow, technical, and economically meaningful — generate almost all of the judgment calls a CFO or controller actually has to make.
Below is a working framework for the five that recur most, plus the documentation pattern that turns a reasonable accounting position into one your auditors and SEC reviewers will sign off on.
The default: ASC 730 expense-as-incurred
ASC 730 requires research and development costs to be charged to expense when incurred. The FASB concluded that the future economic benefit of R&D is too uncertain at the point of expenditure to justify deferral — a conclusion that holds across the full pre-clinical-to-approval continuum.
What counts as R&D is broader than the lab: internal headcount, consumables, CROs and CMOs, IND-enabling studies, all phases of clinical trials, regulatory filings, allocated facilities and IT, and stock-based compensation for R&D employees. Capitalization questions arise only where a specific exception applies.
Exception 1: Acquired IPR&D — business combination vs. asset acquisition
The single most economically significant exception is how acquired in-process R&D is treated, and the answer turns on whether the transaction is a business combination under ASC 805 or an asset acquisition.
Business combination (ASC 805). Acquired IPR&D is recognized as an indefinite-lived intangible at fair value on the acquisition date, not amortized while in process, and tested for impairment annually. At regulatory approval, it's reclassified to a finite-lived intangible and amortized.
Asset acquisition. Acquired IPR&D with no alternative future use is expensed at acquisition. This is the rule that catches biotech teams off-guard: an in-licensing or asset deal — almost always cheaper, faster, and tax-friendlier than a business deal — can run the entire upfront consideration allocated to the in-process program through the income statement on day one.
ASU 2017-01 raised the bar for what qualifies as a business. The "screen test" — if substantially all the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets, it's an asset acquisition — has tipped many biotech deals out of business-combination territory. A single development-stage compound, even with associated employees and contracts, often fails the test.
What to document: A screen-test memo executed at signing, before close, walking through the single-asset concentration analysis and (if the screen fails) the substantive process / substantive output analysis under ASC 805-10-55. Review it with your auditors before close — the income statement impact of getting it wrong is too large to relitigate after the fact.
Exception 2: The "alternative future use" test for tangible assets
ASC 730-10-25-2 requires R&D costs to be expensed except where the cost relates to materials, equipment, or facilities that have an alternative future use beyond the specific project. Where alternative future use exists, the cost is capitalized and depreciated through R&D expense over the asset's useful life.
A bioreactor that can support multiple programs or commercial manufacturing has alternative future use and is capitalized; a single-use disposable lot of media tied to one batch is expensed. A general GMP clean room with utility across the pipeline is capitalized; a dedicated, program-specific facility with no realistic redeployment is expensed. The trap is capitalizing equipment that is, in substance, single-use. Auditors test this with capital project descriptions, board-approved capex, and post-close redeployability — so the defensible position requires engineering specs and a written redeployability assessment, not just a label.
Exception 3: Internal-use software for R&D systems
Software developed or acquired for internal use — LIMS, EDC, CTMS, regulatory submission platforms, QMS — is governed by ASC 350-40, not ASC 730. Application development stage costs are capitalized; preliminary project stage and post-implementation costs are expensed.
Two practical points biotech teams miss. First, the capitalization window is narrower than it looks: it starts only after management has authorized funding and completed conceptual formulation. Training, data migration, and post-go-live enhancements are not capitalizable. Second, SaaS implementation costs follow a separate rule under ASU 2018-15 — they're capitalized as a prepaid asset and amortized over the hosting term, not as software.
Exception 4: Pre-commercial inventory and probability of approval
Inventory built ahead of regulatory approval — pre-launch supply, pre-validation lots, registration batches — is one of the most judgment-heavy areas in biotech accounting, and an area SEC staff revisit often.
The default treatment is to expense pre-commercial inventory as R&D, because at the point of production there is no realizable economic benefit without approval. Capitalization under ASC 330 becomes appropriate only when realization is probable — typically demonstrated by FDA approval or, at minimum, a strong combination of positive Phase III data, a PDUFA date with a high expectation of approval, no major outstanding regulatory or manufacturing issues, and a credible launch plan.
The cleanest practice for most pre-commercial biotech assets is to defer capitalization until actual approval — capitalize prospectively from that date, leave pre-approval production in R&D expense, and avoid the asymmetric risk of an over-capitalization writedown that catches the market by surprise. Whatever the policy, document the trigger event in a board- or audit-committee-reviewed memo and revisit it each quarter.
Exception 5: Upfront fees, milestones, and collaboration payments
Biotech development is increasingly collaborative — in-licensing, out-licensing, co-development, options. The accounting depends on what the payment buys and which side of the agreement you're on.
Payments out. Upfront payments for an in-licensed compound with no alternative future use are expensed under ASC 730-10-25-2(c). Development and regulatory milestones are recognized as R&D expense when payable. Sales milestones and royalties are recognized when the underlying sales occur, in cost of sales. Equity issued in lieu of cash is measured at fair value and follows the same classification.
Payments in. Out-licensing and collaboration receipts are governed by ASC 606 if the counterparty is a customer, or by ASC 808 if the arrangement is a true collaboration sharing risks and rewards. Most large pharma deals contain both — the licensing element under ASC 606, joint research activities under ASC 808 — and require bifurcation.
What to document: A contract-specific accounting memo at signing of any material collaboration walking through the unit of account, classification of each payment stream, timing of recognition, and disclosure implications. These agreements are reviewed in detail by SEC staff during S-1 and 10-K reviews; the memo is the evidence the policy is supportable.
Clinical trial accruals: the discipline that prevents restatements
Clinical trial expense is rarely a capitalization question, but it is the single largest source of in-period adjustments and the most common cause of restatements among pre-commercial biotech filers. For a Phase III program with multiple CROs and dozens of sites, the gap between cost incurred and cost invoiced can run into the tens of millions at quarter-end.
Strong processes share four elements: contract-by-contract budgeting decomposed to the activity level with explicit drivers (per-patient, per-visit, per-monitor-day, fixed-fee milestone); driver-based progress measurement at period end from clinical operations; independent CRO confirmation against the company's accrual; and true-up discipline where recurring true-ups above 5–10% signal a process weakness rather than a normal range. For SOX issuers, this is one of the areas auditors test most directly — strong process pays off in shorter closes and fewer adjustments; weak process is a likely material weakness.
The documentation pattern auditors look for
Across all five exceptions, the documentation that distinguishes a supportable position from a contested one shares a recognizable pattern: a dated accounting policy memo signed off by the controller and CFO; contemporaneous evidence (contracts, board minutes, regulatory correspondence, third-party valuation reports) created at the time of the decision rather than retrospectively; consistency in how the same fact pattern is treated across periods; and disclosure in the financial statement footnotes that ties cleanly to the policy.
For biotech, the right R&D capitalization policy isn't the most aggressive one. It's the one where every position is documented at the time of the decision, applied consistently across the pipeline, and disclosed clearly enough that a reader of the financials can see what the company has done and why.
What boards and audit committees should ask each quarter
Three questions surface most of the R&D accounting risk for biotech companies — particularly those approaching IPO or in their first years as a public company. Have any in-licensing, asset purchase, or business combination transactions closed this quarter, and has the screen test been documented and reviewed with the auditors? For any pre-commercial program approaching approval, what is the trigger to begin capitalizing inventory, and has management's analysis been updated? And for any material new collaboration or license agreement, has an accounting memo been prepared at signing — and does the disclosure in the upcoming filing match the memo's conclusion?
Each has a defensible answer in most quarters. The point of asking is to make sure the answer is being articulated and documented before the auditor or SEC staff asks the same question with less time to respond. If you're working through any of these areas and want a second set of eyes on the memo, the contract, or the close process, we'd be glad to help.
This article is for general informational purposes and should not be relied on as accounting, tax, or legal advice for any specific transaction. Please consult with your advisors.